Biotech entrepreneur #Oncology #Immunology- BiPER Therapeutics CEO & Co-Founder First In Class therapeutics to treat GI Cancers - G.CLIPS Biotech Board Member
Joined June 2009
- Tweets 908
- Following 374
- Followers 173
- Likes 595
9 Photos and videos
4 Feb 2024
BiPER Therapeutics is committed to the fight against cancer / BiPER Therapeutics est engage dans la luttte contre le cancer Let s fight together ! #WorldCancerDay #CloseTheCareGap
2
42
Mehdi Chelbi retweeted
8 Jan 2024
What a great start of 2024! Excited, happy and proud to share our latest work published today #openaccess @NatureMedicine on the PANDA trial: neoadjuvant atezo chemo in pts with gastric/GEJ cancers followed by surgery. Some of the key findings below. 1/10 nature.com/articles/s41591-0…
11
64
208
46,531
Mehdi Chelbi retweeted
5 Jan 2024
GI cancers are the main cause of cancer-related deaths worldwide including 1/3 of deaths related to cancers. Yet research is underfunded and hospital staff is underrepresented.
New research - Wang et al - Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN
thelancet.com/journals/langa…
#GITwitter #OncTwitter @IARCWHO
12
38
3,522
Mehdi Chelbi retweeted
23 Nov 2023
GRP78 is a promising new pan-cancer target for CAR-T therapy (but with a twist). Great preclinical study by @Jorge88382322 @GiedreKrenciute @PaulinaV_MD and the St Jude team cell.com/cell-reports-medici…
2
12
72
7,006
Mehdi Chelbi retweeted
20 Apr 2023
Our SnapShot on Cancer Chemotherapy has just been published in
@CellCellPress bit.ly/3og6XSc
#Cancer #Chemotherapy #CancerResearch
1
6
16
865
Mehdi Chelbi retweeted
27 Jul 2023
🔥Just out: The ESMO #GastricCancer Living Guideline
👉get the latest news & updates for daily decision making
@myESMO @OncoAlert
121
235
26,585
Mehdi Chelbi retweeted
25 Jun 2023
'BRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist'
shorturl.at/hyR04
My husband and I share our views on #BRAFV600E #CRC as a #patient and a #caregiver with the expert Christelle de la Fouchardière
3
7
14
3,349
Mehdi Chelbi retweeted
26 Jun 2023
Revealing the signaling of complement receptors C3aR and C5aR1 by anaphylatoxins | Nature Chemical Biology nature.com/articles/s41589-0…
1
3
365
Mehdi Chelbi retweeted
8 Jun 2023
New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer bit.ly/3quY1JZ @VanMorrisMD @mdmanishshah @DrRonanKelly
1
29
42
14,108
Mehdi Chelbi retweeted
16 May 2023
At @ASCO, @BeiGeneGlobal presented positive results from their phase 3 study of tislelizumab plus chemotherapy as a first-line treatment of advanced gastric cancer that demonstrated meaningful improvement in overall survival. businesswire.com/news/home/2…
1
5
564
Mehdi Chelbi retweeted
7 May 2023
✳️A nice article showing tumor mutation burden alone relatively irrelevant for IO response among MSS GI cancers particularly for MSS CRC❗️
Why?👇
@OncoAlert @TheColonClub @TheColonClub @manjuggm @UPMCHillmanCC
thelancet.com/journals/lanon…
2
37
91
19,422
Mehdi Chelbi retweeted
25 Mar 2023
Thanks to all the speakers, posters, and listeners who attended our first Symposium of 2023: “Recent Advances in Understanding Challenging GPCRs”🙌
Speeding GPCR drug discovery is possible thanks to you all, from all corners of the world 🌍
➡️bit.ly/3JFBrUT
#gpcr #drg…
1
5
474
24 Mar 2023
BiPER Therapeutics fait partie de le selection @Challenges des 100 start ups ou #investir. Notre candidat medicament a une approche unique pour traiter les patients atteints de #Cancers gastrointestinaux www-challenges-fr.cdn.amppro…
1
19
Nature research paper: Autoregulation of GPCR signalling through the third intracellular loop go.nature.com/3FbqgSF
6
50
32,200
Optimal #antibody effectiveness depends on the level of affinity binding. For blocking antibodies, a high affinity may be most effective. However, for agonist antibodies, recent results suggest that intermediate affinity works best, for #immunotherapy.
nature.com/articles/d41586-0…
16
44
4,196
28 Feb 2023
Thanks for sharing Dr @jsoriamd impressive cohort of GI tumors
Not all TMB-high are created equal & predict for #immunotherapy efficacy. In GI cancers with MSS & TMB-high, mutations in SMAD2, MTOR, NFE2L2, RB1, KEAP1, TERT, & RASA1 were associated with suppressed tumor immune environment. sciencedirect.com/science/ar…
36
Mehdi Chelbi retweeted
28 Feb 2023
🔥Current developments in gastric cancer: from molecular profiling to treatment strategy
@NatRevGastroHep
doi.org/10.1038/s41575-022-0…
👏Extensive review & summary of key trials
😅Claudia 18.2 can be added, FGFR2 hopefully soon -> on the way to #PrecisionOncology
@myESMO @OncoAlert
3
70
149
13,045
Mehdi Chelbi retweeted
14 Feb 2023
Cancers gastro-intestinaux : BiPER Therapeutics lève 1,25 million d’euros en amorçage pour développer des petites molécules first-in-class mypharma-editions.com/cancer…
1
2
20
Mehdi Chelbi retweeted
14 Feb 2023
French biotechnology company BiPER Therapeutics has raised €1.25 million to target gastrointestinal cancers. 👇🏻
#biotech #lifesciences #news
labiotech.eu/trends-news/bip…
3
5
620
14 Feb 2023
Great news BiPER Therapeutics raises 1.25 M€ in Seed financing to bring first-in-class #therapeutics to the clinic to treat #GICancer #gastric #cancer #colorectal #cancer #oesophageal #cancer #pancratic #cancer
14 Feb 2023
[ALA Client News] BiPER Therapeutics raises €1.25 million in seed funding to develop first-in-class small molecules to treat gastrointestinal cancers
ala.associates/funding/biper…
#fundraising #oncology
3
168